Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
- Status
- RECRUITING
- Phase
- PHASE4
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
- Status
- COMPLETED
- Phase
- NA
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- Status
- RECRUITING
- Phase
- PHASE2
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Status
- RECRUITING
- Phase
- PHASE3
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
- Status
- RECRUITING
- Phase
- NA
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2